Skye Bioscience (NASDAQ:SKYE - Get Free Report) announced its earnings results on Friday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02), reports.
Skye Bioscience Stock Performance
SKYE traded up $0.09 during midday trading on Monday, hitting $11.41. 40,900 shares of the company traded hands, compared to its average volume of 35,662. The business has a 50 day simple moving average of $13.17 and a two-hundred day simple moving average of $8.93. Skye Bioscience has a 52-week low of $1.44 and a 52-week high of $19.41.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on SKYE. Oppenheimer assumed coverage on Skye Bioscience in a research note on Friday, April 12th. They issued an "outperform" rating and a $25.00 target price on the stock. Piper Sandler restated an "overweight" rating and set a $20.00 price target (up previously from $12.00) on shares of Skye Bioscience in a research report on Thursday, March 14th.
Check Out Our Latest Analysis on Skye Bioscience
Skye Bioscience Company Profile
(
Get Free Report)
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Skye Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skye Bioscience wasn't on the list.
While Skye Bioscience currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
